1001353-92-9

Basic information

• Product Name: (R)-3-Amino-1-methyl-piperidine
• Synonyms: (R)-3-Amino-1-methyl-piperidine;(R)-3-AMino-1-Methyl-pipe...;(R)-1-Methylpiperidin-3-aMine dihydrochloride;(R)-1-Methylpiperidin-3-amine;(R)-1-Methyl-3-aminopiperidine;(3R)-1-Methylpiperidin-3-amine;3-Piperidinamine, 1-methyl-, (3R)-
• CAS NO: 1001353-92-9
• Molecular Formula: C6H14N2
• Molecular Weight: 114
• Mol File: 1001353-92-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 136.5±8.0 °C(Predicted)
• Appearance: /
• Density: 0.912±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.40±0.20(Predicted)
• CAS DataBase Reference: (R)-3-Amino-1-methyl-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-Amino-1-methyl-piperidine(1001353-92-9)
• EPA Substance Registry System: (R)-3-Amino-1-methyl-piperidine(1001353-92-9)

Safety Data

• Hazardous Substances Data: 1001353-92-9(Hazardous Substances Data)

Usage

Uses

(3R)-1-Methyl-3-piperidinamine is used in preparation of Ph benzoimidazole derivatives as antitumor agents.

Upstream product

• 309956-78-3 (R)-piperidin-3-ylcarbamic acid tert-butyl ester 

Downstream Products

• 1233211-24-9 C₂₃H₂₆BrN₃ 
• 1233211-19-2 C₂₂H₂₄BrN₃ 

Relevant articles and documents

TROPANE COMPOUNDS

A compound according to Formula I or II: (I) or (II) wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S

The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group R0; (e) a group R a; (f) a group Rlb; (g) a group Rlc; (h) a group Rld; and 0) 2,6-difluorophenylamino ; wherein R )0υ, r R> llaa, T Rj I1bD, T R) I1cC, r R> Iidα, r R?2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdkl or cdk2) and glycogen synthase kinase-3 activity.